Development pipeline
Twelve disclosed investigational countermeasures and three surgical platforms, built in eighteen months on $310 million of research and development. Seven of the twelve target organisms are Risk Group 4 and not one of the twelve diseases has an approved treatment. Updated 31 August 2026. The research and development figure covers thirteen clinical-stage programmes, of which twelve are described here.
Medicines
Select a candidate for programme detail and a downloadable fact sheet.
| Candidate | Indication | Therapeutic area | Modality | Stage |
|---|---|---|---|---|
| BX-101 Nipavir Fact sheet (PDF) | Nipah virus infection (henipavirus encephalitis) BSL-4 · case fatality 40–75% | Henipaviruses & Emerging Zoonoses | Fusion (F) protein inhibitor, oral | Phase 1 SENTINEL-1 Discovery · IND · Ph1 · Ph2 · Ph3 |
| BX-204 Marburavir Fact sheet (PDF) | Marburg virus disease BSL-4 · case fatality 24–88% | Filovirus Disease | L-polymerase inhibitor, IV & oral | Phase 1 CORDON-1 Discovery · IND · Ph1 · Ph2 · Ph3 |
| BX-308 Prionex Fact sheet (PDF) | Sporadic & genetic Creutzfeldt–Jakob disease CL3 + prion · case fatality ~100% | Prion & Protein-Misfolding Disease | PRNP antisense oligonucleotide, intrathecal | Phase 1 VIGIL-0 Discovery · IND · Ph1 · Ph2 · Ph3 |
| BX-412 Cehafex Fact sheet (PDF) | Crimean-Congo haemorrhagic fever BSL-4 · case fatality 10–40% | Viral Haemorrhagic Fever | Neutralising antibody cocktail, IV | Phase 1 BASTION-1 Discovery · IND · Ph1 · Ph2 · Ph3 |
| BX-515 Lassivar Fact sheet (PDF) | Lassa fever BSL-4 · case fatality 15–20% of hospitalised cases | Arenavirus Disease | GPC-B site monoclonal antibody, IV | Phase 1 TRAVERSE-1 Discovery · IND · Ph1 · Ph2 · Ph3 |
| BX-620 Rabivex Fact sheet (PDF) | Symptomatic rabies encephalomyelitis CL3 · case fatality ~100% once symptomatic | Lyssavirus & Neurotropic Infection | CNS-penetrant L-polymerase inhibitor, IV & intrathecal | Phase 1 LANTERN-1 Discovery · IND · Ph1 · Ph2 · Ph3 |
| BX-733 Hantrelvir Fact sheet (PDF) | Hantavirus cardiopulmonary syndrome CL3 · case fatality 35–40% | Hantavirus & Vascular Leak Syndromes | Host-directed S1PR1 agonist, IV & oral | Phase 1 RIDGELINE-1 Discovery · IND · Ph1 · Ph2 · Ph3 |
| BX-806 Sudanavir Fact sheet (PDF) | Sudan ebolavirus disease BSL-4 · case fatality 41–71% | Filovirus Disease | Two-antibody cocktail, IV | Phase 1 KEYSTONE-1 Discovery · IND · Ph1 · Ph2 · Ph3 |
| BX-1140 Poxavir Fact sheet (PDF) | Clade I mpox & orthopoxvirus disease CL3 · case fatality 1.4–3.3%, higher in children and advanced HIV | Orthopoxvirus Disease | p37 envelope inhibitor, oral & IV | Phase 1 MERIDIAN-1 Discovery · IND · Ph1 · Ph2 · Ph3 |
| BX-1265 Arenavir Fact sheet (PDF) | South American haemorrhagic fevers BSL-4 · case fatality 15–30% untreated | Arenavirus Disease | Pan-arenavirus fusion inhibitor, IV & oral | Phase 1 CROSSBAR-1 Discovery · IND · Ph1 · Ph2 · Ph3 |
| BX-1330 Riftavir Fact sheet (PDF) | Severe Rift Valley fever CL3 enhanced · case fatality >50% in the haemorrhagic form | Phlebovirus & Arboviral Encephalitis | Gn antibody with polymerase inhibitor, IV | Phase 1 HEADWATER-1 Discovery · IND · Ph1 · Ph2 · Ph3 |
| BX-1620 Meliovex Fact sheet (PDF) | Melioidosis (Burkholderia pseudomallei) CL3 · Tier 1 select agent · ~89,000 deaths a year | High-Consequence Bacterial Infection | Efflux-potentiated beta-lactam, IV & oral | Phase 1 REDLAND-1 Discovery · IND · Ph1 · Ph2 · Ph3 |
| Programme 9 designation withheld No fact sheet | Not disclosed in this revision Containment requirement not disclosed | Not disclosed | Not disclosed | Phase 1 Study identifier withheld Discovery · IND · Ph1 · Ph2 · Ph3 |
Thirteen rows. The stage filter above counts twelve, because it reads the disclosed indication field and Programme 9 does not have one. Programme 9 is a real clinical-stage programme and is at the stage shown. Everything else about it is withheld under the disclosure policy and there is no timetable for publishing it. Please do not write to ask. Every disclosed row has a fact sheet; all twelve are also collected in the document library, alongside a pipeline overview (PDF) that carries a half-page profile of each programme.
Surgical technology
| Platform | What it does | Intended use | Status |
|---|---|---|---|
| Lumavue™ | Real-time tissue perfusion imaging | General, colorectal and reconstructive surgery | FDA 510(k) cleared |
| SealWeave™ | Bioresorbable staple-line sealant | Gastrointestinal and thoracic surgery | Phase 1 clinical evaluation |
| Axion OR™ | Robotic soft-tissue instrument platform | Minimally invasive abdominal surgery | Phase 1 clinical evaluation |
How the portfolio got here
Eight more programmes into the clinic
BX-515, BX-620, BX-733, BX-806, BX-1140, BX-1265, BX-1330 and BX-1620 cleared their Investigational New Drug applications between December 2025 and June 2026 and are now all in Phase 1. Three of the eight — BX-515, BX-620 and BX-733 — were listed as discovery-stage candidates on this page as recently as July 2026. Two of the eight, BX-733 and BX-1620, are the first programmes in the portfolio whose regulatory route is a conventional randomised controlled trial rather than the Animal Rule, because unlike Nipah or Marburg their target diseases produce enough cases each year to enrol one.
Into the clinic, and into containment
BX-101, BX-204, BX-308 and BX-412 all entered Phase 1 within a twelve-month window. The Palm Coast maximum-containment suit laboratory completed commissioning in July, moving all Category A pathogen work in-house. Lumavue received FDA 510(k) clearance the same month.
Founded and built
Company incorporated in March, discovery and containment-level 3 laboratories opened in August, the surgical engineering facility opened in November.
Discovery stage
Not counted in the thirteen clinical-stage programmes. Detail on the biocontainment page. The three candidates listed here in the July revision — BX-515, BX-620 and BX-733 — have all cleared an Investigational New Drug application since and now appear in the table above. Two further discovery-stage candidates are not listed. A third row headed BX-6██ was published here between 30 May and 19 June 2026 and was removed.
| Candidate | Target disease | Approach | Stage |
|---|---|---|---|
| BX-841 | Nipah virus (second-generation, inhaled prophylaxis) | Aerosolised prefusion F-directed antibody fragment | Lead optimisation |
| BX-955 | Kyasanur Forest disease and Alkhurma haemorrhagic fever (flavivirus, BSL-4) | NS5 methyltransferase inhibitor | Preclinical |
| BX-1072 | Lujo virus and undescribed Old World arenaviruses | Pan-arenavirus antibody, complementary epitope to BX-1265 | Discovery |
| BX-1188 | Chapare and Sabiá virus (New World arenavirus, BSL-4) | Host cathepsin-dependent entry blocker | Discovery |